A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors.
Pacey, S Garcia-Corbacho, J Lipplaa, A Fusi, Alberto Kumar, S Hategan, M Derham, J Laviste, Glenda Halford, S
Pacey, S
Garcia-Corbacho, J
Lipplaa, A
Fusi, Alberto
Kumar, S
Hategan, M
Derham, J
Laviste, Glenda
Halford, S
Citations
Altmetric:
Abstract
Description
Date
2016-10-01
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors. 2016, 27(suppl_6):1082P Annals of Oncology